CompletedPhase 3NCT02631876
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
Studying Primary peritoneal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ImmunoGen, Inc.
- Principal Investigator
- CMO ImmunoGenImmunoGen, Inc.
- Intervention
- Mirvetuximab soravtansine(drug)
- Enrollment
- 366 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2016 – 2020
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
- Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
- UCLA Women's Health Clinical Research Unit - OBGYN, Los Angeles, California, United States
- University of California San Diego Medical Center, San Diego, California, United States
- California Pacific Medical Center, San Francisco, California, United States
- Kaiser Permanente Medical Center, Vallejo, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- Norwalk Hospital/WCHN, Norwalk, Connecticut, United States
- Florida State University College of Medicine, Sarasota, Florida, United States
- Georgia Regents University (GRU)-Medical College of Georgia (MCG) - Cancer Center, Augusta, Georgia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Sudarshan Sharma LTD, Hinsdale, Illinois, United States
- Community Health Network, Inc., Indianapolis, Indiana, United States
- Indiana University School of Medicine, Indianapolis, Indiana, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Gynecologic Oncology Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02631876 on ClinicalTrials.govOther trials for Primary peritoneal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07480954Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Beijing Biotech
- RECRUITINGPHASE1, PHASE2NCT07322094CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerTORL Biotherapeutics, LLC
- RECRUITINGPHASE3NCT06915025Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerImunon
- RECRUITINGPHASE2NCT07023484Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerThe University of Hong Kong
- RECRUITINGPHASE2NCT06639074Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT TrialMayo Clinic
- RECRUITINGPHASE1NCT06469281A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron Pharmaceuticals
- RECRUITINGPHASE2NCT06492070Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersEmory University
- RECRUITINGPHASE2NCT06434610A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Shanghai Jiaolian Drug Research and Development Co., Ltd